Shire offers up big 'un for Baxalta buyout

Shire has signed an $18bn loan with two underwriters to fund the cash component of its $32bn acquisition of Baxalta, a pharmaceuticals company specialising in rare diseases. Syndication of the loan will begin swiftly, according to bankers familiar with the transaction.